Jantien Wanders

Docetaxel and cisplatin: an active regimen in patients with locally advanced, recurrent or metastatic squamous cell carcinoma of the head and neck. Results of a phase II study of the EORTC Early Clinical Studies Group.

L. Gras, J. Wanders, J. Verweij, 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase II trial with S-1 in chemotherapy-naïve patients with gastric cancer. A trial performed by the EORTC Early Clinical Studies Group (ECSG).

J. Wanders, J. Schellens, V. Grünwald, 2003, European journal of cancer.

Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer.

G. Peters, J. Wanders, F. Caponigro, 2002, European journal of cancer.

Immunisation of metastatic cancer patients with MAGE-3 protein combined with adjuvant SBAS-2: a clinical report.

S. Aamdal, J. Wanders, A. Eggermont, 2003, European journal of cancer.

A phase I study of E7080, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumours

J. Wanders, J. Schellens, J. Beijnen, 2012, British Journal of Cancer.

Docetaxel: an active new drug for treatment of advanced epithelial ovarian cancer.

M. Piccart, M. Gore, J. Wanders, 1995, Journal of the National Cancer Institute.

Phase I study of Carzelesin (U-80,244) given (4-weekly) by intravenous bolus schedule

M. Piccart, J. Verweij, C. Punt, 1999, British Journal of Cancer.

Phase I trial of 6-hour infusion of glufosfamide, a new alkylating agent with potentially enhanced selectivity for tumors that overexpress transmembrane glucose transporters: a study of the European Organization for Research and Treatment of Cancer Early Clinical Studies Group.

P. Beale, J. Wanders, N. Pavlidis, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I and pharmacokinetic study of Yondelis (Ecteinascidin-743; ET-743) administered as an infusion over 1 h or 3 h every 21 days in patients with solid tumours.

J. Wanders, J. Beijnen, J. Smyth, 2003, European journal of cancer.

Phase II study of eribulin mesylate (E7389) in patients with metastatic castration-resistant prostate cancer stratified by prior taxane therapy.

J. Maroto, G. Sonpavde, J. Wanders, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.